The US Food and Drug Administration should exercise “great caution” in allowing a COVID-19 vaccine to be deployed through an emergency use authorization rather than through the preferred route of a biologics license application approval, the National Vaccine Advisory Committee said.
The preference for a BLA over an EUA is one of five recommendations NVAC mades in a letter to Brett...







